Company Filing History:

8 out of 3,681

Bristol-myers Squibb Compnay

patents

3 out of 330

Isis Innovation Limited

patents

1 out of 41

Bristol Meyers Squibb Company

patents

4. 1 out of 84

Cytomx Therapeutics, Inc.

patents

Years Active: 1997-2020

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10800850 - Therapeutic antibodies (2020-10-13),

2. 8623357 - Therapeutic antibodies (2014-01-07),

3. 8440190 - Antibody variants (2013-05-14),

4. 7915395 - Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell (2011-03-29),

5. 7465790 - Therapeutic antibodies (2008-12-16),

6. 6482919 - Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell (2002-11-19),

7. 6384198 - Methods for inhibiting the production of HIV-1 retrovirus using monoclonal antibodies and Fv specific for CD2 antigen (2002-05-07),

8. 6132992 - Expression vectors encoding bispecific fusion proteins and methods of (2000-10-17),

9. 6010902 - Antibody heteroconjugates and bispecific antibodies for use in (2000-01-04),

10. 5876950 - Monoclonal antibodies specific for different epitopes of human GP39 and (1999-03-02),

11. 5807734 - Monoclonal antibodies and FV specific for CD2 antigen (1998-09-15),

12. 5795572 - Monoclonal antibodies and FV specific for CD2 antigen (1998-08-18),

13. 5637481 - Expression vectors encoding bispecific fusion proteins and methods of (1997-06-10),

Title: Celebrating the Innovations of Inventor Lisa K Gilliland

Introduction: Lisa K Gilliland, based in Oxford, GB, is an accomplished inventor with an impressive portfolio consisting of 13 patents. Her work primarily focuses on the development of therapeutic antibodies, highlighting her significant contributions to the pharmaceutical industry.

Latest Patents: Among her latest inventions, Lisa has developed a pharmaceutical comprising a therapeutic protein that binds to a therapeutic target. This innovative protein is modified with a compound that inhibits binding to the therapeutic target, effectively reducing immune responses against it. By doing so, the modified protein serves to produce a therapeutic effect through its interaction with the therapeutic target. Notably, this therapeutic protein may include an antibody with a combining site dedicated to binding with the therapeutic target.

Career Highlights: Lisa has built a distinguished career, having contributed her expertise to notable companies such as Bristol-Myers Squibb Company and Isis Innovation Limited. Her dedication to the field of therapeutic innovation has made a lasting impact on the development of new treatments.

Collaborations: In her professional journey, Lisa has collaborated with distinguished colleagues such as Jeffrey A Ledbetter and Peter S Linsley. These collaborations reflect her commitment to teamwork and advancing the field of therapeutic pharmaceuticals.

Conclusion: Lisa K Gilliland’s innovative work in the realm of therapeutic antibodies has positioned her as a prominent figure in pharmaceutical research. Her 13 patents are a testament to her creativity and dedication, contributing significantly to improving therapeutic approaches in modern medicine.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

1 patent (EPO):

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.